Of spiders and crabs: The emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer

Mandi Murph, Tamotsu Tanaka, Shuying Liu, Gordon B. Mills

    Research output: Contribution to journalArticle

    46 Scopus citations


    Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), two small lysophospholipids, are potent inducers of many of the hallmarks of cancer including cell proliferation, survival, migration, invasion, and neovascularization in in vitro and in vivo tumor models. Furthermore, the enzymes metabolizing LPA and S1P and their receptors are aberrant in multiple cancer lineages and exhibit transforming activity altering patterns and targets for metastasis. Several recent studies show the remarkable activity of new chemical genomics and/or potential novel drugs in preclinical models. Combined with the physiologic and pathophysiologic activities of LPA and S1P, these studies suggest the implementation of preclinical and clinical evaluation of LPA and S1P as therapeutic targets.

    Original languageEnglish (US)
    Pages (from-to)6598-6602
    Number of pages5
    JournalClinical Cancer Research
    Issue number22
    StatePublished - Nov 15 2006


    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this